Skip to main content

NCI SBIR Impact Study

NCI has one of the largest SBIR and STTR programs in the United States. In 2017, the NCI SBIR Development Center hired TechLink to help quantify the program’s overall contribution to the national economy.

The study examined the economic outcomes and impacts leading up to 2018 from all NCI SBIR/STTR Phase II awards initiated from FY 1998 to FY 2010. A total of 444 companies received Phase II funding for 690 separate projects over the period.

For more information about the NCI SBIR Economic Impact Study, please see the study brief or the full report.

$9.1 billion in total sales to date of products and services resulting from the NCI SBIR/STTR Phase II awards
$26.1 billion in total economic output nationwide
$13.4 billion in value added, representing new wealth creation in the economy

Other economic outcomes include:

  • Total outside investment funding: $4.26 billion
  • Total acquisition value of companies acquired: $21.63 billion
  • Number of technologies licensed to other companies: 103
  • Number of spin-out companies created: 45
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “NCI SBIR Impact Study was originally published by the National Cancer Institute.”